Recent BDRX News
- Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting • GlobeNewswire Inc. • 05/21/2024 12:30:00 PM
- Posting of Annual Report & Notice of AGM - Total Voting Rights • GlobeNewswire Inc. • 05/15/2024 07:57:55 AM
- Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting • GlobeNewswire Inc. • 04/30/2024 03:51:56 PM
- Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) • GlobeNewswire Inc. • 04/26/2024 12:30:00 PM
- Preliminary Results for the Year Ended 31 December 2023 • GlobeNewswire Inc. • 04/19/2024 12:00:00 PM
- Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update • GlobeNewswire Inc. • 02/23/2024 01:30:00 PM
- Biotech Shares Bid Up Premarket Following 9.9% Institutional Stake Disclosure • AllPennyStocks.com • 02/13/2024 01:15:00 PM
- Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients • GlobeNewswire Inc. • 02/08/2024 01:30:00 PM
- Biodexa Announces Allowance of U.S. Patent Covering Tolimidone • GlobeNewswire Inc. • 02/07/2024 01:30:00 PM
- Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024 • GlobeNewswire Inc. • 01/22/2024 01:30:00 PM
- Biodexa Appoints Ann Merchant to the Board of Directors • GlobeNewswire Inc. • 12/29/2023 09:05:00 AM
- Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option • GlobeNewswire Inc. • 12/21/2023 09:00:00 PM
- Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering • GlobeNewswire Inc. • 12/19/2023 01:42:13 PM
- Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes • GlobeNewswire Inc. • 11/27/2023 02:00:00 PM
- Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma • GlobeNewswire Inc. • 10/03/2023 12:30:00 PM
- Interim results for the six months ended 30 June 2023 • GlobeNewswire Inc. • 09/29/2023 08:30:00 PM
- Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO) • GlobeNewswire Inc. • 09/21/2023 12:30:00 PM
- Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites • GlobeNewswire Inc. • 07/28/2023 12:00:00 PM
- Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement • GlobeNewswire Inc. • 07/24/2023 11:30:00 AM
- Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs) • GlobeNewswire Inc. • 07/10/2023 12:00:00 PM
- Results of Appeal of Delisting Determination • GlobeNewswire Inc. • 07/06/2023 08:30:00 PM
- Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) • GlobeNewswire Inc. • 07/06/2023 12:15:00 PM
- ADR Ratio Change • GlobeNewswire Inc. • 06/22/2023 08:15:00 PM
- Appeal of Delisting Determination • GlobeNewswire Inc. • 06/20/2023 12:00:00 PM
- Receipt of NASDAQ Delisting Determination Plans to Appeal • GlobeNewswire Inc. • 06/15/2023 08:05:00 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM